2024
- October 1, 2024 Announcement of Change in Business Scheme of Insomnia Treatment QUVIVIQ® (PDF 64KB)
- September 24, 2024 Announcement of Manufacturing and Marketing Approval of Insomnia Treatment QUVIVIQ® in Japan (PDF 133KB)
- September 24, 2024 Mochida Obtained Approval for an Additional Indication of TREPROST® Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease in Japan (PDF 314KB)
- August 2, 2024 [Summary] Consolidated Financial Results for the Three Months Ended June 30, 2024 (PDF 721KB)
- July 22, 2024 Mochida Filed a Partial Change Application in Approved Matters of Ulcerative Colitis Treatment LIALDA® to Add Dosage and Administration for Pediatric Patients in Japan (PDF 306KB)
- July 16, 2024 Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 (PDF 189KB)
- July 2, 2024 Announcement of Submission of New Drug Application for Epadel in China (PDF 105KB)
- July 2, 2024 Mochida Pharmaceutical Obtains 510(k) Clearance for "ReFeel®", a Material that Supports Nerve Regeneration, in the United States (PDF 220KB)
- May 31, 2024 NOTICE OF THE 86th ORDINARY GENERAL MEETING OF SHAREHOLDERS (PDF 412KB)
- May 16, 2024 FY2023 Financial Results Presentation (PDF 1,219KB)
- May 13, 2024 [Summary]Consolidated Financial Results for the Year Ended March 31, 2024 (PDF 736KB)
- February 5, 2024 [Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2023 (PDF 894KB)
2023
- December 25, 2023 Mochida Filed an Application for Approval of an Additional Indication for TREPROST® Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease or Combined Pulmonary Fibrosis and Emphysema, in Japan (PDF 291KB)
- November 2, 2023 [Summary] Consolidated Financial Results for the Six Months Ended September 30, 2023 (PDF 778KB)
- November 1, 2023 Announcement of the Sales Partnership Agreement in Japan between Mochida and Shionogi regarding Insomnia Treatment Drug Daridorexant (PDF 169KB)
- October 31, 2023 Announcement of Application for Manufacturing and Marketing Approval of Insomnia Treatment Daridorexant in Japan (PDF 81KB)
- August 4, 2023 [Summary] Consolidated Financial Results for the Three Months Ended June 30, 2023 (PDF 677KB)
- June 5, 2023 NOTICE OF THE 85th ORDINARY GENERAL MEETING OF SHAREHOLDERS (PDF 342KB)
- May 15, 2023 [Summary]Consolidated Financial Results for the Year Ended March 31, 2023 (PDF 561KB)
- April 24, 2023 The Launch of Treprost® Inhalation Solution, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 112KB)
- March 28, 2023 The contract for the joint commercialization of HLC-001 in regenerative medicine products (PDF 227KB)
- March 22, 2023
Senju initiated Phase III Clinical Trials in Japan for “SJP-0132” for the treatment of Dry Eye Disease
The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju (PDF 168KB)
2022
- December 23, 2022 Mochida Obtains Marketing Approval for Treprost® Inhalation Solution, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 110KB)
- May 20, 2022 “MOVICOL® HD” Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan (PDF 232KB)
- May 13, 2022 The Mochida Pharmaceutical Group’s “22-24 Medium-Term Management Plan” (PDF 441KB)
- February 4, 2022 Mochida files New Drug Application for MD-711, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 36KB)
2021
2020
- May 27, 2020 The NHI Drug Price Listing and Launch of DINAGEST Tablets 0.5mg, a Treatment for Dysmenorrhea (PDF 104KB)
- April 1, 2020 The Mochida Pharmaceutical Group’s “20-22 Medium-Term Management Plan” (PDF 183KB)
- January 23, 2020 Mochida Obtains Marketing Approval in Japan for DINAGEST Tablets 0.5 mg for the Treatment of Dysmenorrhea (PDF 101KB)
2019
- December 5, 2019 Mochida Pharmaceutical Announce a License Agreement for the Co-development and Co-marketing of daridorexant, an Investigational Therapeutic Agent for Insomnia, in Japan (PDF 301KB)
- November 27, 2019 The NHI Drug Price Listing and Launch of Teriparatide BS MOCHIDA, a Treatment for Osteoporosis, in Japan (PDF 171KB)
- September 20, 2019 Mochida obtains marketing approval for teriparatide biosimilar in Japan (PDF 184KB)
- April 1, 2019 The Mochida Pharmaceutical Group’s “19-21 Medium-Term Management Plan” (PDF 98KB)
- February 8, 2019 Mochida files application for marketing and manufacturing approval of the indication for dysmenorrhea for “Dinagest,” in Japan (PDF 37KB)
2018
- November 29, 2018 MOVICOL® Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan (PDF 211KB)
- September 21, 2018 Marketing and Manufacturing Approval of Chronic Constipation Treatment “MOVICOL®” Obtained in Japan (PDF 164KB)
- July 9, 2018 Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment“GOOFICE® 5mg Tablet” Published in The Lancet Gastroenterology & Hepatology (PDF 212KB)
- May 30, 2018 The NHI Drug Price Listing and Launch of Etanercept Biosimilar in Japan (PDF 93KB)
- May 28, 2018 PⅢ Clinical Study Data on Chronic Constipation Treatment“GOOFICE® 5mg Tablet” Will Be Presented at DDW2018 (PDF 180KB)
- April 19, 2018 World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan (PDF 247KB)
- April 2, 2018 The Mochida Pharmaceutical Group’s “18-20 Medium Term Management Plan” (PDF 114KB)
- January 19, 2018 Mochida obtains marketing approval for etanercept biosimilar in Japan (PDF 107KB)
- January 19, 2018 New drug approval of bile acid transporter inhibitor “GOOFICE® 5mg Tablet” for chronic constipation was obtained in Japan (PDF 138KB)
2017
- November 27, 2017 Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan (PDF 108KB)
- September 29, 2017 Joint Development and Marketing Agreement for Chronic Constipation Treatment AJG555 in Japan Was Signed (PDF 34KB)
- April 3, 2017 The Mochida Pharmaceutical Group’s “17-19 Medium Term Management Plan” (PDF 80KB)
- March 28, 2017 Distribution Rights Agreement for Tyvaso®, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 41KB)
- February 1,2017 New Drug Application of AJG533 for chronic constipation was filed in Japan. (PDF 77KB)
2016
- December 2,2016 Announcement of approval for an additional indication for therapeutic agent for endometriosis, “Dinagest Tab. / OD Tab.” in Japan (PDF 41KB)
- November 18,2016 The NHI Drug Price Listing and Launch of LIALDA®, a Once-Daily Treatment for Ulcerative Colitis (PDF 45KB)
- September 30,2016
EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce the results of phase 3 study of AJG533 for chronic constipation conducted in Japan
―Primary endpoint was met in patients with chronic constipation (PDF 42KB) - September 30,2016 Revised agreement for the commercialization of TRAMCET® Combination Tablets for the relief of chronic non-cancer pain and pain after tooth extraction (PDF 60KB)
- September 28,2016 Mochida obtains marketing approval for LIALDA®, a Once-Daily Treatment for Ulcerative Colitis, in Japan (PDF 19KB)
- April 1, 2016 The Mochida Pharmaceutical Group’s “16-18 Medium Term Management Plan” (PDF 78KB)
- January 27, 2016 Announcement of an application for approval of an additional indication for therapeutic agent for endometriosis, “Dinagest Tab. / OD Tab.” in Japan (PDF 14KB)
2015
- November 20, 2015 Announcement of an approval for an additional indication for the Anti-depressant, Lexapro® Tablets 10mg in Japan (PDF 56KB)
- October 30, 2015 Mochida files New Drug Application for MD-0901, a Once-Daily Treatment for Ulcerative Colitis, in Japan (PDF 19KB)
- May 15, 2015 Mochida announces Termination of License Agreement with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (PDF 14KB)
- April 1, 2015 The Mochida Pharmaceutical Group’s “15-17 Medium Term Management Plan” (PDF 112KB)
2014
2013
2012
2011
- December 13, 2011 Mochida announces License Agreement with Merck (PDF 19KB)
- October 3, 2011 The Mochida Pharmaceutical Group’s “11-13 Medium Term Management Plan” (PDF 64KB)
- July 21, 2011 The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro® 10 mg (PDF 16KB)
- April 22, 2011 Mochida receives an approval for an Anti-depressant, Lexapro® 10 mg in Japan (PDF 19KB)
2010
- December 14, 2010 Conclusion of Comprehensive License and Collaboration Agreement with Gedeon Richter concerning Biosimilar Product Portfolio (PDF 63KB)
- September 15, 2010 Mochida files New Drug Application for an Anti-depressant, Escitalopram in Japan (PDF 55KB)
- April 13, 2010 Mochida announces Termination of License Agreement with Wyeth (PDF 39KB)
- April 1, 2010 Overview of the Mochida Pharmaceutical Group’s “10-12 Medium Term Management Plan” (PDF 89KB)
- January 7, 2010 Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan (PDF 35KB)
2009
- April 30, 2009 Conclusion of Distributorship Agreement Concerning Switch-OTC Drug for Hyperlipidemia Treatment, Epadel (PDF 14KB)
- April 1, 2009 Overview of the Mochida Pharmaceutical Group’s “09-11 Medium Term Management Plan” (PDF 11KB)
- January 16, 2009 Mochida Concludes License Agreement for LIALDA® - A Once-Daily Treatment for Ulcerative Colitis (PDF 14KB)
2008
- April 1, 2008 Overview of the Mochida Pharmaceutical Group’s “08-10 Medium Term Management Plan” (PDF 82KB)
- March 3, 2008 Transfer of Marketing Authorizations and Distribution Rights for Bone Metabolism Marker “OSTEOMARK” and “OSTEOMARK NTx SERUM” (PDF 34KB)
- January 9, 2008 Mochida Announces Conclusion of License Agreement with Wyeth (PDF 14KB)
- January 7, 2008 Mochida Launches Dinagest Tab. 1mg - A Treatment for Endometriosis (PDF 15KB)
2007
- November 26, 2007 Mochida Launches Beselna Cream 5% - First Therapeutic Agent for Condyloma Acuminatum in Japan (PDF 35KB)
- October 22, 2007 Mochida Obtains Approval for Dinagest Tab. 1mg - A Treatment for Endometriosis (PDF 14KB)
- April 2, 2007 Overview of the Mochida Pharmaceutical Group’s “07-09 Medium Term Management Plan” (PDF 82KB)
Acrobat Reader 
is required for News Releases. Acrobat Reader is offered gratuitously by Adobe Systems.
